A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis
Status:
Recruiting
Trial end date:
2021-07-28
Target enrollment:
Participant gender:
Summary
A dose escalation, first-in-human study evaluating the safety, tolerability,
pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects and
subjects with moderate- to- severe atopic dermatitis